compared with healthy subjects and their associations with antidepressant response. Methods: We investigated the changes of several cytokines (eotaxin, sCD40L, by Luminex assay in 66 patients with MDD and 22 healthy controls. The antidepressant response was assessed by 17-item Hamilton Rating Scale for Depression. Results: We found the levels of sCD40L (p=0.001), and MCP-1 (p=0.03) of healthy controls were significantly higher than those of depressive patients. However, the level of eotaxin and TNF-alpha were not associated with MDD. In addition, we found the level of MCP-1 was significantly changed after antidepressant treatment (p=0.01). Conclusions: These findings suggest the roles of cytokines in MDD are complex, and could vary according to the individual characteristics of each patient. Further studies regarding the relationship between cytokines and MDD will be required. Keywords: Antidepressants, depression, immune system Corresponding author: Doh Kwan Kim (paulkim@skku.edu)
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Do SSRIs cause an initial increase in suicidal ideation and anxiety in patients with depression participating in placebo-controlled trials?
Jakob Näslund, University of Gothenburg, Sweden Abstract Background and objective: Selective serotonin reuptake inhibitors (SSRIs) have been reported to elicit or aggravate certain psychiatric symptoms, such as anxiety and -controversiallysuicidal ideation, during the first days of drug administration, but the frequency of such reactions remains largely unknown. In this study, patient-level data from 8205 adult subjects with depression that had participated in drug company-sponsored placebo-controlled trials regarding sertraline, paroxetine or citalopram were analyzed, the aim being to explore the prevalence of an SSRI-induced increase in anxiety-related symptoms or suicidal ideation shortly after treatment onset. Methods: Analyses were carried out on relevant items of the HAM-D depression rating scale. Likelihood of early worsening as well as mean scores for the SSRI and placebo groups were compared using a generalized linear mixed model and a linear mixed model respectively. Results: After one week of drug administration, the mean rating of somatic anxiety was higher in SSRI-treated subjects than in those given placebo (1.41 ± 0.017 vs 1.34 ± 0.011, p<0.001), as was the percentage of subjects reporting an increase in this symptom (9.4% vs 6.7%, p<0.001). In contrast, mean ratings of psychic anxiety and suicidal ideation, as well as the percentage of subjects showing a decline in these symptoms, was significantly lower in those given SSRI than in the placebo group (psychic anxiety: 1.88 ± 0.017 vs 1.96 ± 0.018, p<0.001; 7.1% vs 8.5%, p<0.001; suicidal ideation: 0.72 ± 0.012 vs 0.78 ± 0.012, p<0.001; 5.1% vs 7.3%, p<0.001). The data confirms that SSRIs may elicit heightened anxiety during the first days of treatment in depressed patient but also suggest this to be a rare phenomenon. Conclusion: Whereas the results do not permit the conclusion that SSRIs never enhance suicidal ideation, they indicate that such an effect cannot be frequent, and that, already after the first week of treatment, it is more common that they dampen suicidal ideation. Abstract Objective: Depressive disorders typically emerge during early adolescence and adulthood, and if left untreated, increase risk of chronicity, morbidity and mortality. Pharmacotherapy with selective serotonin reuptake inhibitors (SSRIs) is first-line treatment, though increased risk of suicidality with SSRI use in youth populations is cautioned in the literature. Escitalopram is a newer SSRI with superior efficacy and tolerability to other SSRIs, but without data specifically in early depression patients. The aim of this study was to investigate the efficacy, safety and tolerability of escitalopram monotherapy in young adult patients with first-episode depression. Methods: Forty-two (42) patients, 18-29 years, medication-free and diagnosed with first-episode depression, were recruited. Open-label escitalopram was administered for 16 weeks at flexible dose (5-30 mg/day). The primary efficacy measure was the 17-item Hamilton Depression Scale (HAMD-17). The secondary efficacy measures were the Beck Depression Inventory (BDI) and the Neo Personality Inventory (NEO-PI-R). All measures were completed at baseline, 8 weeks and 16 weeks. Safety and tolerability were assessed via questioning at each patient visit. Results: Between baseline and 16 weeks, there was a significant decrease in depression scores on the HAMD-17 (p<0.001) and BDI (p<0.0001). On the NEO-PI-R, there was a significant decrease in neuroticism (p=0.003), and significant increase in extraversion (p=0.0002) and openness to experience (p<0.0001). The response rate was 77% and the remission rate was 64%. The mean dose at 16 weeks was 19.05 mg/day, with no significant difference between responders and non-responders (p=0.06). Side effects reported were mild, consisted mainly of dry mouth and nausea, and did not lead to discontinuation. Conclusions: Open-label escitalopram was effective in improving both symptoms and functioning in young adults with first-episode depression. It was also well tolerated. Limitations include lack of placebo control, non-randomized design and small sample size.
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Open (Haykal & Akiskal, 1999) . Desvenlafaxine is effective in the treatment of major depression (Thase et al., 2009 ), yet there is no data on its efficacy in the treatment of persistent depressive disorder. The aim of this study was to investigate the efficacy, safety and tolerability of desvenlafaxine monotherapy in patients with persistent depressive disorder. Methods: Thirty-five patients with persistent depressive disorder consented to participate in an open-label 8-week trial of monotherapy with desvenlafaxine. Primary efficacy measures were
